Merck (MRK) Stock Sinks As Market Gains: Here's Why
In the closing of the recent trading day, Merck (MRK) stood at $123.54, denoting a -1.22% move from the preceding trading day.
MRK - Merck & Co., Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$135.33
DETAILS
HIGH:
$155.00
LOW:
$100.00
MEDIAN:
$140.50
CONSENSUS:
$135.33
UPSIDE:
9.54%
Stock News
FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Adults With Muscle-Invasive Bladder Cancer (MIBC)
RAHWAY, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Merck's anti-PD-1 therapies, each in combination with Padcev® (enfortumab vedotin-ejfv), as neoadjuvant treatment and then continued after cystectomy as adjuvant treatment for the treatment of adult patients with muscle-invasive bla.
Why Investors Need to Take Advantage of These 2 Medical Stocks Now
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?
VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.
MRK Surpasses 50- & 200-Day SMAs: Buy, Hold or Sell at Current Levels?
MRK trades above its 50- and 200-day SMAs as pipeline progress, acquisitions and Keytruda strength offset patent and vaccine headwinds.
Merck To Rally More Than 16%? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
The Dividend ETF Quietly Outperforming the S&P 500
This dividend ETF's focus beyond yield continues to pay off for investors.
Merck (MRK) Stock Slides as Market Rises: Facts to Know Before You Trade
Merck (MRK) concluded the recent trading session at $126.78, signifying a -2.15% move from its prior day's close.
Why MSTY Shareholders Are Facing Uncapped Losses Despite Weekly Distributions
The YieldMax MSTR Option Income Strategy ETF (NYSEARCA:MSTY) is the single-stock income product retail investors flocked to when MicroStrategy (now Strategy) was climbing alongside Bitcoin.
Merck & Co Inc (MRK) Shares Surge 3.3% -- What GF Score of 78 Tells Investors
On July 02, 2026, Merck and Co Inc (MRK) shares rose 3.3% today, currently priced at $129.56. The stock has experienced significant price appreciation, trading wi
Merck Stock, JPMorgan And Two Others Hit New Highs
Merck stock is in a buy zone after hitting a new high. Fellow Dow stock JPMorgan Chase and Amphenol are both trading around entry points.
Schwab vs. Vanguard: Which Dividend ETF Is Best for Your Portfolio?
Portfolio concentration and sector weightings set these two popular income funds apart for investors seeking steady cash flow.
Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4
RAHWAY, N.J.--(BUSINESS WIRE)--Merck to Hold Second-Quarter 2026 Sales and Earnings Conference Call Aug. 4.
Merck, AbbVie probed by US lawmakers over China clinical trials: report
A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck and AbbVie, were involved in clinical trials conducted in China that may have supported the country's military capabilities, according to a Reuters report. The inquiry, led by Republican Representative John Moolenaar of Michigan, chair of the House Select Committee on China, focuses on whether the drugmakers conducted adequate due diligence and maintained sufficient data protection standards at trial sites in China.
Stock Futures Quiet to End the Month, Quarter
Stock futures are pointed lower to end the month and quarter as AI capex concerns linger
Merck, AbbVie probed by US lawmakers over China clinical trials: report
A bipartisan group of United States lawmakers has opened national security investigations into whether five major pharmaceutical companies, including Merck...
Recursion Pharmaceuticals vs. Summit Therapeutics: Which Healthcare Stock Is a Better Buy in 2026?
Recursion harnesses AI for large-scale drug discovery, while Summit's betting on a single oncology candidate. How do their financials and risk profiles stack up?
Merck & Company (MRK) Price Forecast: Can Momentum Drive New Highs?
Merck extends its bullish breakout from a pennant pattern, supported by strong volume and higher swing lows, with technical structure pointing toward continued upside potential.
Is Merck (MRK) a Buy as Wall Street Analysts Look Optimistic?
When deciding whether to buy, sell, or hold a stock, investors often rely on analyst recommendations. Media reports about rating changes by these brokerage-firm-employed (or sell-side) analysts often influence a stock's price, but are they really important?
Price Targets
Merck price target raised to $150 from $135 at HSBC
$150.00
(was $126.05)
Rajesh Kumar
·
HSBC
Merck (MRK) PT Raised to $141 at BofA Securities
$141.00
(was $129.38)
Jefferies
Merck price target raised to $155 from $136 at Scotiabank
$155.00
(was $129.38)
Scotiabank
Guggenheim Reiterates Buy Rating on Merck (MRK)
$140.00
(was $115.21)
Vamil Divan
·
Guggenheim
Merck price target raised to $112 from $109 at Morgan Stanley
$112.00
(was $112.47)
Terence Flynn
·
Morgan Stanley
Merck (MRK) PT Raised to $150 at Wells Fargo
$150.00
(was $116.22)
Mohit Bansal
·
Wells Fargo
RBC Capital Starts Merck (MRK) at Outperform
$142.00
(was $123.93)
Trung Huynh
·
RBC Capital
Merck upgraded to Buy from Hold at Deutsche Bank
$150.00
(was $121.53)
James Shin
·
Deutsche Bank
Merck price target raised to $133 from $120 at Goldman Sachs
$133.00
(was $115.86)
Asad Haider
·
Goldman Sachs
Merck price target raised to $135 from $130 at BMO Capital
$135.00
(was $115.86)
BMO Capital
Merck price target raised to $100 from $95 at Bernstein
$100.00
(was $115.86)
Bernstein
Merck price target raised to $136 from $120 at Scotiabank
$136.00
(was $116.37)
Scotiabank
Merck price target raised to $116 from $83 at Cantor Fitzgerald
$116.00
(was $107.40)
Cantor Fitzgerald
Merck upgraded to Outperform from Peer Perform at Wolfe Research
$135.00
(was $108.59)
Wolfe Research
Merck price target raised to $130 from $105 at UBS
$130.00
(was $110.96)
UBS
Merck upgraded to Outperform from Market Perform at BMO Capital
$130.00
(was $99.21)
BMO Capital
Merck price target raised to $102 from $100 at Morgan Stanley
$102.00
(was $100.06)
Morgan Stanley
Merck price target raised to $120 from $100 at HSBC
$120.00
(was $96.89)
Rajesh Kumar
·
HSBC
Merck price target raised to $122 from $104 at Guggenheim
$122.00
(was $100.89)
Guggenheim
Merck price target raised to $120 from $105 at Scotiabank
$120.00
(was $101.88)
Louise Chen
·
Scotiabank